Document is current

Any future updates will be listed below

Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Crossref DOI link: https://doi.org/10.1186/s13046-025-03383-x

Published Online: 2025-04-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark